Indivior on Monday sold off the rights to an opioid withdrawal drug in China for up to $122.5 million (£93.6 million).
The group will sell the Sai Bo Song tablets to Hangzhou-based vaccine maker Pukang Biotechnology.
China has an estimated 7.3 million people dependent on opioids, according to the latest figures.
Indivior will get $17.5 million up front and up to $105 million more depending on certain sales targets being met over the next decade.
Indivior chief executive Shaun Thaxter said offloading the tablets was “consistent with Indivior’s efforts” to focus on its other well-known drugs, Sublocade and Perseris.
“With its knowledge of the local environment and scientific heritage, we believe Pukang is well suited to advance the science of addiction treatment in China,” he added.
The deal is expected to close by the end of the year.
Indivior has also struck a deal with rival Alvogen to stop it from selling a cheaper version of its Suboxone drug until a US court case is settled.
